Literature DB >> 22735379

Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.

Anna-Mary Young1, Kyra M Archibald, Laura A Tookman, Alexander Pool, Kate Dudek, Carolyn Jones, Sarah L Williams, Katrina J Pirlo, Anne E Willis, Michelle Lockley, Iain A McNeish.   

Abstract

Adaptive immune responses may be vital in the overall efficacy of oncolytic viruses in human malignancies. However, immune responses to oncolytic adenoviruses are poorly understood because these viruses lack activity in murine cells, which precludes evaluation in immunocompetent murine cancer models. We have evaluated human adenovirus activity in murine cells. We show that a panel of murine carcinoma cells, including CMT64, MOVCAR7, and MOSEC/ID8, can readily be infected with human adenovirus. These cells also support viral gene transcription, messenger RNA (mRNA) processing, and genome replication. However, there is a profound failure of adenovirus protein synthesis, especially late structural proteins, both in vitro and in vivo, with reduced loading of late mRNA onto ribosomes. Our data also show that in trans expression of the nonstructural late protein L4-100K increases both the amount of viral mRNA on ribosomes and the synthesis of late proteins, accompanied by reduced phosphorylation of eIF2α and improved anticancer efficacy. These results suggest that murine models that support human adenovirus replication could be generated, thus allowing evaluation of human adenoviruses in immunocompetent mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735379      PMCID: PMC3437579          DOI: 10.1038/mt.2012.116

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

1.  Adenovirus-specific translation by displacement of kinase Mnk1 from cap-initiation complex eIF4F.

Authors:  R Cuesta; Q Xi; R J Schneider
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Regulation of translation by ribosome shunting through phosphotyrosine-dependent coupling of adenovirus protein 100k to viral mRNAs.

Authors:  Qiaoran Xi; Rafael Cuesta; Robert J Schneider
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

4.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Productive replication of human adenoviruses in mouse epidermal cells.

Authors:  I Ganly; V Mautner; A Balmain
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes.

Authors:  A R Fattaey; E Harlow; K Helin
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

7.  Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus.

Authors:  M Suomalainen; M Y Nakano; K Boucke; S Keller; U F Greber
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

8.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Authors:  C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

9.  Development of a syngeneic mouse model for events related to ovarian cancer.

Authors:  K F Roby; C C Taylor; J P Sweetwood; Y Cheng; J L Pace; O Tawfik; D L Persons; P G Smith; P F Terranova
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

Review 10.  Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies.

Authors:  Giuseppina D'Andrilli; Christine Kumar; Giovanni Scambia; Antonio Giordano
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

View more
  19 in total

1.  Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors:  Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 2.  Murine adenoviruses: tools for studying adenovirus pathogenesis in a natural host.

Authors:  Silvio Hemmi; Katherine R Spindler
Journal:  FEBS Lett       Date:  2019-12-06       Impact factor: 4.124

3.  Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.

Authors:  Monika Sobočan; Daniela Brunialti; Sussanne Sprung; Christoph Schatz; Jure Knez; Rajko Kavalar; Iztok Takač; Johannes Haybaeck
Journal:  J Ovarian Res       Date:  2022-06-19       Impact factor: 5.506

4.  Effective Apical Infection of Differentiated Human Bronchial Epithelial Cells and Induction of Proinflammatory Chemokines by the Highly Pneumotropic Human Adenovirus Type 14p1.

Authors:  Elena Lam; Mirja Ramke; Gregor Warnecke; Sonja Schrepfer; Verena Kopfnagel; Thomas Dobner; Albert Heim
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

Review 5.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.

Authors:  Zong Sheng Guo; Zuqiang Liu; David L Bartlett
Journal:  Front Oncol       Date:  2014-04-10       Impact factor: 6.244

Review 6.  Oncolytic viruses as therapeutic cancer vaccines.

Authors:  David L Bartlett; Zuqiang Liu; Magesh Sathaiah; Roshni Ravindranathan; Zongbi Guo; Yukai He; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2013-09-11       Impact factor: 27.401

7.  A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.

Authors:  L Zhang; F Hedjran; C Larson; G L Perez; T Reid
Journal:  Cancer Gene Ther       Date:  2014-12-19       Impact factor: 5.987

8.  The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Authors:  Anne Kleijn; Jenneke Kloezeman; Elike Treffers-Westerlaken; Giulia Fulci; Sieger Leenstra; Clemens Dirven; Reno Debets; Martine Lamfers
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

9.  Vaccinia virus induces programmed necrosis in ovarian cancer cells.

Authors:  Lynsey M Whilding; Kyra M Archibald; Hagen Kulbe; Frances R Balkwill; Daniel Öberg; Iain A McNeish
Journal:  Mol Ther       Date:  2013-09-24       Impact factor: 11.454

10.  Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

Authors:  Hong Jiang; Karen Clise-Dwyer; Kathryn E Ruisaard; Xuejun Fan; Weihua Tian; Joy Gumin; Martine L Lamfers; Anne Kleijn; Frederick F Lang; Wai-Kwan Alfred Yung; Luis M Vence; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.